TScan Therapeutics
TCRX

TScan Therapeutics (TCRX) analyst forecast and price target

Recent analyst ratings

FirmActionRatingPrice targetDate
HC Wainwright & Co.MaintainedBuy$7.00Aug 12, 2026
NeedhamMaintainedBuy$6.00Jun 23, 2026
WedbushMaintainedOutperform$5.00Jun 23, 2026
WedbushMaintainedOutperform$5.00 from $4.00Mar 5, 2026
HC Wainwright & Co.MaintainedBuy$7.00 from $10.00Nov 13, 2025
NeedhamMaintainedBuy$6.00 from $9.00Nov 4, 2025
BTIGDowngradedBuy → NeutralNov 4, 2025
HC Wainwright & Co.MaintainedBuy$10.00 from $15.00May 7, 2025
NeedhamMaintainedBuy$9.00Apr 8, 2025
Morgan StanleyInitiated CoverageOverweight$10.00Mar 14, 2025
BarclaysMaintainedOverweight$3.00 from $14.00Mar 7, 2025
HC Wainwright & Co.MaintainedBuy$15.00Mar 6, 2025
NeedhamMaintainedBuy$9.00 from $11.00Mar 5, 2025
NeedhamMaintainedBuy$11.00Dec 11, 2024
HC Wainwright & Co.MaintainedBuy$15.00Dec 11, 2024
HC Wainwright & Co.MaintainedBuy$15.00Nov 15, 2024
NeedhamMaintainedBuy$11.00Nov 12, 2024
NeedhamMaintainedBuy$11.00Nov 6, 2024
HC Wainwright & Co.MaintainedBuy$15.00Aug 13, 2024
WedbushMaintainedOutperform$10.00Aug 13, 2024

Frequently asked questions

  • What is the latest analyst rating on TCRX?

    On Aug 12, 2026, HC Wainwright & Co. maintained TScan Therapeutics at Buy with a price target of $7.00.

Analyst ratings and price targets are the opinions of third-party research firms, not of Light Horse Securities. They are estimates about an uncertain future, are frequently wrong, and are neither a recommendation nor a prediction of actual results.

This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.